Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
With the gradual prolongation of the overall survival of cancer patients, the cardiovascular toxicity associated with oncology drug therapy and radiotherapy has attracted increasing attention. At present, the main methods to identify early cancer treatment-related cardiac dysfunction (CTRCD) include...
Guardado en:
Autores principales: | Huiyu Xiao, Xiaojie Wang, Shuang Li, Ying Liu, Yijie Cui, Xiaoqin Deng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d8c62d5d835547c9919d7652bbbe34d0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Assesment of the TEI index of myocardial performance in dogs with doxorubicin-induced cardiomiopathy
por: Sousa,MG, et al.
Publicado: (2014) -
Role of Cardiac Biomarkers in Cancer Patients
por: Gennaro Carmine Semeraro, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age
por: Raffaella Calabretta, et al.
Publicado: (2021) -
Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Thomas Bartl, et al.
Publicado: (2021) -
Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
por: Can Öztürk, et al.
Publicado: (2021)